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Abstract 
 
Background 
Centrally acting medications cause cognitive slowing and incoordination, which could reduce older 
people’s physical activity levels. This association has not been studied previously. 
 
Objectives 
To examine the association between opioid, hypnotic and anticholinergic medication, and objectively 
measured physical activity, in a cohort of older people. 
 
Methods 
We used data from the Physical Activity Cohort Scotland, a representative cohort of community-
dwelling older people aged 65 and over who were assessed at baseline and again 2-3 years later. 
Objective physical activity was measured using Stayhealthy RT3 accelerometers over 7 days. Baseline 
medication use (opioid use, hypnotic use, modified anticholinergic risk score [mARS]) was obtained 
from linked, routinely collected community prescribing records. Cross-sectional and longitudinal 
associations between baseline medication use and both baseline activity and change in activity over 
time were analysed using unadjusted and adjusted linear regression models. 
 
Results 
310 participants were included in the analysis; mean age 77 (SD 7) years. No association was seen 
between baseline use of any medication class and baseline physical activity levels in unadjusted or 
adjusted models. For change in activity over time, there was no difference between users and non-
users of hypnotics or opioids. Higher anticholinergic burden was associated with a steeper decline in 
activity over the follow up period (mARS=0: -7051 counts/24h/yr; mARS=1-2 -15942 counts/24h/yr; 
mARS>=3 -19544 counts/24h/yr; p=0.03) and this remained robust to multiple adjustments. 
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Conclusion 
Anticholinergic burden is associated with greater decline in objectively measured physical activity over 
time in older people, a finding not seen with hypnotic or opioid use. 
 
 
 
Key points 
 Few studies have examined the association of medication use with habitual physical activity 
in older people 
 Use of opioids, hypnotics and anticholinergics was not associated with objectively measured 
physical activity levels in cross-sectional data 
 Increasing anticholinergic burden was associated with more rapid decline in objectively 
measured physical activity levels over time 
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1. Introduction 
Regular physical activity is known to be associated with a host of health benefits, and is an important 
determinant of health and function in later life. Physical activity helps to protect against cardiovascular 
disease, diabetes, cancer and dementia [1], as well as protecting against the decline in physical 
function that often accompanies old age, and which leads to falls, hospitalisation and care home 
admission. It is therefore particularly concerning that only 7% of men and 4% of women over the age 
of 75 years in the UK reach current physical activity recommendations [2,3]. Interventions to improve 
habitual, everyday physical activity in older people have had only limited success to date, suffering 
from suboptimal efficacy, low uptake and low adherence [4,5]. In order to develop better 
interventions to improve PA in older people, a more complete understanding of the relationships 
between health, disability and activity in older people is desirable, in addition to the interplay between 
these factors and other social, psychological and environmental factors. 
 
One important area that has received little attention to date is the relationship between medication 
use and physical activity in older people [6]. The majority of older people suffer from multimorbidity, 
and hence take multiple medications [7]. Just as some diseases may interfere with the ability to 
undertake physical activity (for instance arthritis, heart failure or lung disease), it is plausible that some 
medications may also interfere with the ability to undertake physical activity. In particular, 
medications that impair brain function and cause drowsiness or confusion might be expected to inhibit 
both the desire and ability to undertake physical activity [8]. 
 
Such medications include sleeping tablets, some antidepressants, opioid painkillers, but also 
importantly medications with anticholinergic side effects. Anticholinergic medications encompass all 
medications with action at acetylcholine receptors, whether such effects are intended or are ‘off-
target’ effects. The majority of side-effects are mediated via multiple muscarinic receptor subtypes, 
and include postural instability, cognitive impairment, dry mouth, constipation, blurred vision and 
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urinary retention. These side effects are shared by a wide range of medications used by older people, 
and the burden of anticholinergic action can be quantified using readily-available scoring systems. 
Existing research has already suggested that increased anticholinergic medication burden is associated 
with an increased risk of earlier death and a higher chance of memory impairment in older people 
[9,10]; higher cumulative exposure to anticholinergic agents is associated with a higher risk of a future 
diagnosis of dementia [11] 
 
In this paper, we analyse data from the baseline and follow up waves of the Physical Activity Cohort 
Scotland (PACS) with the aim of describing a) the cross-sectional association between opioid, hypnotic 
and anticholinergic medication use and physical activity, and b) the association between opioid, 
hypnotic and anticholinergic medication use and change in physical activity over time, in older people. 
 
2. Methods 
 
2.1 Study population 
The Physical Activity Cohort Scotland (PACS) is a representative sample of nearly 600 community 
dwelling older people from Tayside, Scotland. The cohort was sampled to ensure good representation 
of those aged 80 and over, as well as including socially deprived individuals. At baseline, physical 
activity was measured objectively using 7-day triaxial accelerometry; a wide range of psychological, 
behavioural and environmental information was also collected at baseline. The sampling methods and 
baseline results have been described in detail previously [2]. The measurements were repeated on 
approximately 350 cohort members two to three years later [12], when consent was also obtained for 
linkage of PACS data to other routinely collected healthcare data. 
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Written informed consent was obtained from all participants at baseline and at follow up; the study 
was approved by the Tayside Committee on Medical Research Ethics (09/S1401/57 and 12/ES/0016). 
The study conformed to the principles of the Declaration of Helsinki. 
 
2.2 Data linkage 
Data collected during the baseline and follow up study visits were linked to routinely collected clinical 
data for the participants giving consent for this process at the follow up visit. Consent was not sought 
for this process at the baseline visit, hence not all participants could have study data linked to routinely 
collected clinical data. Data linkage was performed by the Health Informatics Centre (HIC), University 
of Dundee, and the linked, de-identified dataset was stored within the HIC Safe Haven environment 
to ensure data security and confidentiality. All analyses were performed within the Safe Haven 
environment. 
 
Sources of routinely collected data were linked via the 10-digit Community Health Index (CHI) number 
assigned to all inhabitants of Scotland. Previous diagnoses of comorbid disease were derived from 
discharge diagnoses held on the SMR01 (Scottish Morbidity Register 01) register, which holds a record 
of all Scottish hospital discharges. A previous diagnosis of cancer within the 5 years prior to study entry 
(excluding basal cell carcinoma of the skin) was derived from SMR06 (Scottish Morbidity Register 06), 
which holds records of all Scottish cancer diagnoses. A diagnosis of diabetes mellitus prior to study 
entry was obtained from the Scottish Care Information – Diabetes Collaboration (SCI-DC) database. 
Community prescribing data, comprising encashed prescriptions, were also linked and used to derive 
medication use. 
 
2.3 Measurement of physical activity 
Physical activity at baseline and follow up visits was measured using the RT3 triaxial accelerometer 
(Stayhealthy Inc, Monrovia, California, USA) worn on the waistband over the same hip during waking 
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hours for a seven-day period. Summed vector magnitude activity counts were recorded each minute 
for 7 days. 24 hour periods commenced at midnight; the partial data from the first and last day was 
therefore discarded leaving a maximum of 6 periods of 24 hours for analysis.  Days with less than 6 
hours of recorded activity data were omitted from analysis. A Freepost envelope was provided in 
which to return the accelerometer. Participants were instructed to remove the device at bedtime, and 
also not to wear the device during bathing and showering. The RT3 has previously been validated in a 
number of different ways: it shows adequate test-retest reliability, it has been shown to discriminate 
walking from sedentary activity in older people, and it is responsive to interventions designed to 
increase physical activity[13-15]. 
 
2.4 Measurement of medication use 
Data on prescriptions dispensed by community pharmacies are collected and held by HIC; these data 
cover all community-dispensed prescriptions in the Tayside area, but do not cover hospital-dispensed 
prescriptions. We defined baseline medication use as any prescription in each category (opioids, 
hypnotics, anticholinergics) in the 90 days prior to the date of the baseline PACS visit. Opioid 
prescriptions were defined as any prescription from category 4.7.2 of the British National Formulary; 
hypnotic prescriptions were defined as any prescription from category 4.1 of the British National 
Formulary, with the exception of melatonin and sodium oxybate. The modified anticholinergic risk 
score (mARS) was calculated using the weightings developed by Rudolph et al [9] and modified by 
Sumukadas et al [16]. A mARS score of 0 denotes no or limited anticholinergic potential; 1 = moderate 
potential, 2 = strong potential and 3 = very strong potential. Although lacking data on dose that 
accompanies some other anticholinergic scales, the ARS has been used in several previous population 
based studies and has been shown to be strongly associated with impaired cognitive and functional 
outcomes[17-19].  
 
2.5 Covariates 
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Three categories of covariates were selected for use in adjusted models. Variables that had previously 
been shown to be independently associated with baseline physical activity in the PACS cohort [2] were 
used: SF-36 physical function, number of people one can turn to in a crisis, high self-efficacy (perceived 
behavioural control from Theory of Planned Behaviour questions), along with age, sex and decile of 
deprivation obtained using the Scottish Index of Multiple Deprivation (SIMD) [20].  Categories of self-
reported comorbid disease recorded by the Older People and Active Living (OPAL) questionnaire [21], 
self-reported chronic pain, and self-reported falls in the year prior to study enrolment were obtained 
from the baseline wave of data collection. We added measures of comorbid disease, but did not 
include measures of environment from baseline as these were not significantly associated with 
baseline activity counts in our previous analysis. Additional comorbid disease diagnoses were obtained 
from ICD-10 coded hospital discharge diagnoses prior to study enrolment, using linked data obtained 
from the SMR01 database. ICD (International Classification of Disease) version 10 codes used to derive 
these diagnoses were: Myocardial infarction: I21, I22; Stroke: I61, I63, I64; Heart failure I50; Chronic 
obstructive pulmonary disease: J41, J42, J43, J44, J47. Objectively diagnosed cancer and diabetes 
mellitus were derived from SMR06 and SCI-DC registers as described above. 
 
2.6 Statistical analysis 
Baseline activity data were known to be highly skewed, and are thus presented as medians with 
interquartile ranges. Unadjusted comparisons of baseline activity between users and non-users of 
each medication class were made using Mann-Whitney U test for two-category comparisons, and 
Kruskal-Wallis test for three-category comparisons. Change in activity levels with time was expressed 
as change per year of follow up; these data were normally distributed and analysis of covariance 
(adjusting for baseline activity count) was used to compare groups. 
 
In order to adjust for baseline covariates, multivariable linear regression models were run, using log-
transformed activity count as the dependent variable. A separate set of models were run using change 
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in activity count between baseline and follow up as the dependent variable. Each model included all 
three medication categories. For each dependent variable, three models were run – firstly adjusting 
for factors known from previous work to be associated with activity counts in this cohort (age, sex, 
deprivation, number of people nearby to turn to, perceived behavioural control, SF-36 physical 
function), secondly adding baseline comorbid disease, chronic pain and falls (as a proxy for frailty), 
and thirdly, adding in the number of medications remaining after accounting for opioids, 
anticholinergics and sleeping medications, as a measure of overall medication burden. All analyses 
were conducted using SPSS v22 (IBM, New York, USA) and a two-sided p value of <0.05 was taken as 
significant for all analyses. 
 
3. Results 
A total of 584 participants were recruited at baseline; 339 of these underwent the follow up 
assessment, and of these, 310 had complete data and form the group analysed here. Details of these 
310 participants at the baseline study visit are shown in Table 1. 
 
Table 2 depicts unadjusted analyses contrasting activity levels and change in activity during follow up 
for baseline users of opioids, hypnotics and anticholinergics. No significant difference was seen in 
baseline activity counts between users and non-users of any medication class, but participants with 
higher baseline mARS scores exhibited a greater decline in objectively measured physical activity 
between baseline and follow up. 
 
Table 3 shows the association between baseline activity counts and medication use after adjustment 
for covariates; Table 4 similarly shows adjusted analyses for the association between baseline 
medication use and change in activity counts. Similar to the unadjusted analyses, no significant 
difference was seen in baseline activity counts between users and non-users of any medication class, 
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but higher baseline mARS remained significantly associated with greater declines in physical activity 
with time, even after adjusting for all covariates. 
 
To further explore the interaction between self-reported pain, opioid use and baseline activity levels, 
we calculated median baseline activity counts in a two-by-two table (Table 5). Self-reported pain was 
associated with lower activity levels, but no significant interaction was found between self-reported 
pain and opioid use on baseline activity levels (p for interaction=0.31) 
 
4. Discussion 
Our analysis found no significant association between objectively measured physical activity and three 
important classes of medications commonly used in older people. However, individuals with a higher 
anticholinergic burden showed a greater decline in their physical activity levels over a 2-3 year follow 
up, and this finding persisted after adjustment for multiple sociodemographic variables and 
comorbidities.  
 
Dissecting out causality from observational studies, even with longitudinal follow-up, is not possible. 
Although our findings suggest that use of anticholinergic medications might contribute to a decline in 
PA, it is equally possible that anticholinergic medication use is a marker for other factors (particularly 
comorbid disease) that drive the decline in PA. However, the association between anticholinergic 
medication and decline in PA was robust to adjustment not only for a series of comorbidities, but also 
for the number of medications, which can be viewed as a surrogate for total burden of comorbidity. 
Anticholinergic medication use has been associated with a range of adverse consequences; a recent 
systematic review highlights associations between anticholinergic use and decline in activities of daily 
living and decline in cognitive function [22], and a recent large case-control study found an increased 
risk of dementia with higher cumulative exposure to anticholinergic agents [11]. These results are 
consistent with our findings; direct effects of anticholinergic medications on cognition could explain 
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some of the reduction in PA seen in the current analysis. Furthermore, anticholinergic medications are 
associated with worse balance and more falls[23]. The mechanism for this finding is unclear but could 
be due both to a reduction in processing speed, and to promotion of cerebral vasculopathy and 
consequent white matter changes. Fear of falls may dissuade individuals from undertaking PA. Finally, 
anticholinergic burden may be associated with a higher incidence of new cardiovascular events[24]; 
this would again be expected to reduce physical activity. 
 
Given the profound effects that hypnotic agents are known to have both on cognitive function and on 
falls risk [25], it is perhaps surprising that use of such agents was not associated with either baseline 
PA or a decline in PA when compared to non-users. Numbers taking this medication class were small, 
limiting the ability of the analysis to detect a significant difference, and it is noteworthy that users had 
both a non-significantly lower level of PA at baseline and a non-significantly greater decline in PA 
during follow up. The lack of significance may therefore be due to a lack of statistical power rather 
than absence of a true association. It is also possible that those at highest risk of adverse effects from 
hypnotics are not prescribed these agents; recent years have seen a focus both on limiting initiation 
of these agents and in deprescribing these agents [7], particularly amongst older people with falls or 
cognitive impairment. 
 
The relationship between opioid use and physical activity is complicated by the effects of confounding 
by indication; opioids are almost always given for pain, and pain is known to be associated with lower 
objectively measured PA [26]. However, opioids have a wide range of side effects, including cognitive 
slowing, constipation, and are associated with increased risk of falls – all of which might reduce PA. 
We did not find an association between opioid use and PA; although participants reporting chronic 
pain had lower PA levels, opioid use did not significantly interact with pain. Our ability to draw 
conclusions from that analysis are limited by the small number of participants who were taking 
opioids. It is interesting to note though that the small number of participants taking opioids who 
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reported no pain (i.e. their pain was controlled), had non-significantly higher activity counts at baseline 
than those taking opioids who were still in pain. It is therefore possible that control of pain is more 
important than opioid use in determining PA levels and future, larger studies could usefully investigate 
this issue further.  
 
Our analysis has several strengths. We used objective measures of physical activity, which are less 
prone to recall bias and are better at detecting low PA levels than self-reported measures in older 
people [27,28]. We measured a wide range of sociodemographic, psychological and environmental 
factors in our cohort, and linking to routinely collected clinical data enables objective diagnostic 
information to be used. Similarly, the use of dispensed prescription data avoids recall bias for 
medication use, and avoids counting prescriptions that were written but never dispensed. 
 
A number of limitations of our analysis require discussion. The statistical power of the analysis was 
weakened by the relatively small sample size, and by dropouts between baseline and follow up. 
Differential dropout is likely to have diluted the effects that we observed; participants who declined 
rapidly are likely to be underrepresented at follow-up as they are more likely to have died or become 
too unwell or frail to participate. We did not make a distinction between weak and strong opioids, nor 
between different doses of hypnotics, opioids or anticholinergics. Whilst doing so might have given 
additional information on dose-response, achieving accurate dose equivalence across different 
medications is very difficult and likely to introduce error. There are a number of different 
anticholinergic scores in use; although we chose one that is appropriate to UK prescribing practice, 
different scales have yielded different strengths of association with outcomes in previous studies [29]. 
Future analyses could be strengthened both by comparing different anticholinergic scales, by 
dissecting out the effects of anticholinergics given for different indications (e.g. for overactive bladder, 
for psychiatric illness, and for other diagnoses) and by examining the cumulative exposure to 
medications in time-dependent analyses.  
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There are now a multitude of physical activity monitors commercially available as technology has 
progressed and a different monitor might more accurately capture physical activity levels in older 
adults than the RT3 monitor used in this study. Soft tissue motion at the waist has been reported to 
induce significant errors in belt worn physical activity monitors and it is possible that more modern 
activity monitors may detect more subtle changes in activity, such as differences in activity patterning 
or in sedentary time [30]. We did not attempt to convert activity counts to activity levels (e.g. 
moderate/vigorous or light activity); thresholds for these measures using the RT3 were established in 
young/middle aged individuals and cannot be considered to be reliable in older people, particularly 
those with poor physical performance [12]. Whilst this hinders attempts to compare our cohort with 
other studies, data from other patient groups where RT3 vector magnitude counts have been used 
reveal that young adults with lower back pain have mean counts approximately twice the level seen 
in our cohort [31]; older people with heart failure [32] or with functional impairment [33] had mean 
counts of between 50% and 70% of that seen in our cohort.   
 
Conclusions 
We found that anticholinergic burden was associated with greater decline in objectively measured 
physical activity over time in older people, a finding not seen with hypnotic or opioid use. Given the 
importance of physical activity levels in older people – both as a factor in developing a range of 
diseases and as a measure of functional ability – more work is needed to understand the relationship 
between medication use and activity levels. Understanding these relationships will assist older people 
and healthcare workers in making optimum choices about medication use so that physical activity is 
not compromised by treatment of other symptoms or disease states. 
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Table 1: Baseline details (n=310) 
 
Variable Mean (SD), Median (IQR) or n (%) 
Mean age (yrs) (SD) 77.3 (7.2) 
Female sex (%) 169 (54.5) 
Median activity count/24hrs (IQR) 141482 (104735) 
Comorbid disease from linked data 
 Chronic heart failure 9 (2.9) 
 Myocardial infarction 9 (2.9) 
 Stroke 5 (1.6) 
 COPD 5 (1.6) 
 Diabetes mellitus 25 (8.1) 
 Cancer (last 5 yrs) 12 (3.9) 
Self-reported illness 
 Rheumatoid arthritis 21 (6.8) 
 Osteoarthritis 58 (18.7) 
 Neurological disease 4 (1.3) 
 Hypertension 150 (48.4) 
 Diabetes mellitus 21 (6.8) 
 Heart disease 95 (30.6) 
 Cancer 14 (4.5) 
 Chronic pain 127 (41.0) 
 Hospital admission in last year 45 (14.5) 
 Fall in last year 90 (29.0) 
Medication use 
 Median total number of 
medications dispensed (IQR) 
5 (5) 
 Median self-reported number of 
medications (IQR) 
3 (5) 
 Taking opioids (%) 16 (5.2) 
 Taking hypnotics (%) 21 (6.8) 
 mARS score mARS 0 (%) 244 (78.6) 
20 
 
  mARS 1-2 (%) 37 (12.0) 
  mARS 3-6 (%) 28 (9.1) 
  mARS >=7 (%) 1 (0.3) 
 
COPD: Chronic obstructive pulmonary disease. mARS: modified Anticholinergic Risk Scale. SD: 
Standard deviation. IQR: Interquartile range 
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Table 2: Unadjusted associations between medication use and baseline activity 
Predictor variable Median count (IQR) p-valuea Change in count per year (95% CI)b p-value 
Hypnotics Non-users 142984 (102507) 
0.37 
-8844 (-12265, -5423) 
0.58 
Users 121789 (104360) -12522 (-25202, 159) 
Opioids Non-users 141124 (103936) 
0.85 
-8498 (-11878, -5118) 
0.13 
Users 159888 (107551) -20006 (-34473, -5539) 
mARS score 0 148181 (108458) 
0.14 
-7051 (-10729, -3372) 
0.03c 1-2 128936 (91458) -15942 (-25346, -6539) 
>=3 121482 (99956) -19544 (-30200, -8887) 
aMann-Whitney U test; Kruskal-Wallis test for mARS score category 
bGeneral linear model, adjusted for baseline count 
cp for trend 
CI: Confidence interval. IQR: Interquartile range. mARS: modified anticholinergic risk score  
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Table 3: Adjusted models for medication use vs log of baseline count/24h. 
Predictor variable 
Model 1 Model 2 Model 3 
B 95% CI for B p-value B 95% CI for B p-value B 95% CI for B p-value 
Opioids 0.064 -0.154, 0.283 0.57 0.051 -0.168, 0.270 0.65 0.064 -0.155, 0.283 0.57 
Hypnotics -0.018 -0.209, 0.174 0.86 -0.026 -0.218, 0.165 0.79 -0.034 -0.225, 0.157 0.73 
mARS score 0 Referent 
0.22 
Referent 
0.34 
Referent 
0.53 1-2 -0.027 -0.174, 0.120 -0.037 -0.186, 0.113 -0.009 -0.162, 0.144 
>=3 -0.099 -0.265, 0.066 -0.084 -0.257, 0.089 -0.061 -0.237, 0.115 
  
Model 1: Adjusted for age, sex, deprivation, number of people nearby to turn to, perceived behavioural control, SF-36 physical function 
Model 2: As for model 1, with the addition of chronic heart failure, myocardial infarction, stroke, chronic obstructive pulmonary disease, diabetes mellitus, 
cancer, hypertension, chronic pain, fall in last year 
Model 3: As for model 2, with the addition of total number of other medications taken at baseline 
 
mARS: modified anticholinergic risk score. CI: confidence interval, SF-36: Short Form 36 health questionnaire 
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Table 4. Adjusted models for medication use vs change in activity (counts/24h) per year of follow up 
Predictor variable 
Model 1 Model 2 Model 3 
B 95% CI for B p-value B 95% CI for B p-value B 95% CI for B p-value 
Opioids -9037 -22755, 4682 0.20 -6928 -20657, 6801 0.32 -6179 -19779, 7421 0.37 
Hypnotics 1666 -10343, 13675 0.79 1167 -10844, 13179 0.85 917 -10956, 12789 0.88 
mARS score 0 Referent 
0.04† 
Referent 
0.04† 
Referent 
0.03† 1-2 -6781 -16103, 2541 -6529 -15904, 2847 -5847 -15335, 3641 
>=3 -10333 -21105, 440 -11493 -22330, -656 -11036 -21971, -101 
 
Model 1: Adjusted for age, sex, deprivation, number of people nearby to turn to, perceived behavioural control, SF-36 physical function and baseline 
counts/24h 
Model 2: As for model 1, with the addition of chronic heart failure, myocardial infarction, stroke, chronic obstructive pulmonary disease, diabetes mellitus, 
cancer, hypertension, chronic pain, fall in last year 
Model 3: As for model 2, with the addition of total number of other medications taken at baseline 
 
mARS: modified anticholinergic risk score. CI: confidence interval, SF-36: Short Form 36 health questionnaire 
†p for trend  
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Table 5: Interaction between self-reported pain, opioid use and median (IQR) activity counts at baseline 
 Opioid use No opioid use p-value 
Self-reported pain 121789 (94699) (n=11) 135237 (81914) (n=116) 0.67 
No self-reported pain 173830 (156977) (n=5) 150283 (119234) (n=174) 0.38 
p-value 0.16 0.04  
IQR: Interquartile range 
